Navigation Links
Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
Date:10/28/2009

and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements an
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
2. Cardiome Pharma Corp. Announces Final Results of Tender Offer
3. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
4. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
5. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
6. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
7. Cardiome to Hold Conference Call
8. Cardiome Announces Management Transition
9. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
10. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
11. Cardiome Reports First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Bio probe being developed, screening women for cervical cancer could ... inserted into the vagina, and the woman herself can do ... measures electrical resistance. ,It is so small that ... than taking up the routine Pap smear that is being ...
... developing fatal heart disease say researchers. A new study ... anxieties including the fear of crowded places, heights or ... psychosocial factors such as emotions, anxiety and anger to ... disease. Studies in men suggest anxiety, specifically phobic anxiety, ...
... to a treatment regimen already consisting of chemotherapy and ... among women with high-risk breast cancer with few long ... 1979 and 1986, 318 patients were randomly assigned to ... a 20-year follow-up, researchers found the chemotherapy/radiation combination, compared ...
... or broiled fish, such as tuna, may lower stroke ... 4,775 adults 65 and older. Study participants answered food-frequency ... 12 years. ,Results showed 626 of the participants ... ate broiled or baked fish one- to four-times per ...
... findings of a recent study researchers say weight gain after ... risk for postmenopausal women who // are not taking hormone ... women, ages 50 to 74, by asking them about their ... the women have been periodically asked to provide updates on ...
... days of physical inactivity, the body's efficient use of insulin ... ,Researchers conducted a study in rats and found insulin sensitivity ... stopped running for two days after a period of running ... muscle in response to insulin was found to have decreased ...
Cached Medicine News:Health News:Understanding The Link Between Phobias And Fatal Heart Disease 2
(Date:12/15/2014)...   DaVita HealthCare Partners Inc.  (NYSE: ... and most innovative health care communities, today announced ... Clinical Research  (DCR) and  HealthCare Partners Clinical Research , ... clinical research and data analytics services, specifically in ... renal disease (ESRD), as well as primary care ...
(Date:12/14/2014)... , Dec. 14, 2014  ChartSpan, a consumer ... most downloaded iPhone and iPad medical app in ... - http://photos.prnewswire.com/prnh/20141214/164317 ChartSpan is ... ability to request, manage and send electronic healthcare records. ... entrepreneurs who grew tired of waiting for the healthcare ...
(Date:12/13/2014)... Dec. 12, 2014  Radiologists can transmit their ... to their referring physicians, electronic health records (EHR) ... selected technology.  That was the ... Corporation (ADS) at the recent Radiology Society of ... of radiology reports in this manner also helps ...
Breaking Medicine Technology:DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 2DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 3DaVita Clinical Research and HealthCare Partners Clinical Research to Merge and Expand Clinical Trials and Data Analytics Capabilities 4ChartSpan Becomes The Most Downloaded Medical App in America 2ChartSpan Becomes The Most Downloaded Medical App in America 3Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 2Advanced Data Systems Presents on Interface-Free EHR Communications at RSNA's 2014 Conference: Streamlining Communication of Reports and Images to Referring Physicians 3
... Sept. 9, 2011 Nektar Therapeutics (Nasdaq: ... company,s Phase 2 clinical study of NKTR-102 in patients ... 2011 Breast Cancer Symposium in San Francisco, California.  NKTR-102 ... proprietary polymer conjugate technology, and is being developed in ...
... BRUSSELS, September 9, 2011 The Board of ... that today it agreed to ratify the proposal of the ... legislative package, designed with the help of EFCG and US ... Drug User Fees Act (GDUFA). GDUFA requires the ...
Cached Medicine Technology:Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 2Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 3Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 4Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 5Positive Results from Phase 2 Clinical Study of NKTR-102 in Metastatic Breast Cancer Presented in Oral Session at the ASCO 2011 Breast Cancer Symposium 6European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: